Biotech Values

[genisi]

Colaris (colorectal and uterine cancer risk) and Colaris AP became commercially available in the U.S. in 2000 and 2002 respectively. Theraguide for predicting adverse events from 5-FU, was launched in July 2007, so perhaps it needs a couple of more years.